Dyno Therapeutics Announces Presentations at 2021 American Society of Gene and Cell Therapy Annual Meeting

Company will deliver three oral abstracts and host an Industry Symposium

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dyno Therapeutics, a biotech company applying artificial intelligence (AI) to gene therapy, today announced that it will deliver three oral presentations and an Industry Symposium at the 24th annual meeting of the American Society of Gene and Cell Therapy (ASGCT) being held as a virtual meeting on May 11–14, 2021.

Details for the oral presentations are as follows:

Title: Efficient Design of Optimized AAV Capsids using Multi-property Machine Learning Models Trained across Cells, Organs and Species (Abstract #23)

Presenter: Eric Kelsic, Ph.D., CEO and Co-founder, Dyno Therapeutics

Session: Development of AAV Capsid Variants

Time: 5:45 – 6:00pm EST on Tuesday, May 11

Title: Risk-Adjusted Selection for Validation of Sequences in AAV Design Using Composite Sampling (Abstract #24)

Presenter: Lauren Wheelock, Ph.D., Scientist I, Machine Learning, Dyno Therapeutics

Session: Development of AAV Capsid Variants

Time: 6:00 – 6:15pm EST on Tuesday, May 11

Title: AAV Capsid Property Estimation Is Improved by Combining Single-Molecule ID Tags and Hierarchical Bayesian Modeling of Experimental Processes (Abstract #190)

Presenter: Kathy Lin, Ph.D., Sr. Scientist, Computational Biology, Dyno Therapeutics

Session: Novel AAV Biology and Platform Technologies

Time: 6:15 – 6:30pm EST on Thursday, May 13

Dyno will also host an Industry Symposium entitled “Building Dyno Therapeutics” from 5:15 – 6:45pm EST on Thursday, May 13. During this interactive session, employees throughout the company will describe the breakthroughs that enabled Dyno’s approach to AAV capsid engineering, how the company is inventing new methods for machine learning and quantitative high-throughput in vivo experimentation, and the story of developing a world-class team and culture alongside groundbreaking science.

About CapsidMap™ for Designing Optimized AAV Gene Therapies

Dyno’s CapsidMap™ platform overcomes the limitations of gene therapies on the market and under development today by optimizing capsids, the cell-targeting protein shells of Adeno-Associated Virus (AAV) vectors. Current gene therapies primarily use a small number of naturally occurring capsids that are limited by delivery efficiency, pre-existing immunity, payload size, and manufacturing challenges. CapsidMap works in two stages, first by measuring capsid properties in high-throughput using next-generation DNA library synthesis and DNA sequencing. With these vast quantities of in vivo data, CapsidMap then generates improved capsid sequences by applying advanced search algorithms that leverage machine learning. Dyno’s comprehensive map of capsid sequence space and AI-powered tools thereby accelerate the design of AAV gene therapies with optimized properties including improved safety, manufacturability and applicability for treating a broader range of diseases.

About Dyno Therapeutics

Dyno Therapeutics is a pioneer in applying artificial intelligence (AI) and quantitative high-throughput in vivo experiments to gene therapy. The company’s proprietary CapsidMap™ platform rapidly discovers and systematically optimizes Adeno-Associated Virus (AAV) capsid vectors that significantly outperform current approaches for in vivo gene delivery, thereby expanding the range of diseases treatable with gene therapies. Dyno was founded in 2018 by experienced biotech entrepreneurs and leading scientists in the fields of gene therapy and machine learning. The company is located in Cambridge, Massachusetts. Visit www.dynotx.com for additional information.


Kathryn Morris

The Yates Network



error: Content is protected !!